PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health

PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial

PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment